yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital. .
marketwatch: "new migraine drugs have promise -- and a ,500 price tag." .
biohaven: "rimegepant pivotal phase 3 trial results -- conference call." .